- Home
- SBET vs INBX Comparison
SBET vs INBX Comparison
Compare SBET & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | INBX |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2025 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SBET | INBX |
|---|---|---|
| Price | $9.48 | $102.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $18.71 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 8.0M | 306.3K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | $1,300,000.00 |
| Revenue This Year | $105.19 | N/A |
| Revenue Next Year | $13.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | 550.00 |
| 52 Week Low | $4.46 | $28.16 |
| 52 Week High | $19.53 | $155.29 |
Technical Indicators
Market Signals| Indicator | SBET | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 46.35 |
| Support Level | $7.85 | $96.60 |
| Resistance Level | $10.46 | $106.40 |
| Average True Range (ATR) | 0.55 | 6.82 |
| MACD | 0.02 | -1.90 |
| Stochastic Oscillator | 68.09 | 18.19 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.